Cell Cycle Kinetic Analysis of Colorectal Neoplasms Using a New Automated Immunohistochemistry-Based Cell Cycle Detection Method

Ayako Tomono, MD, Tomoo Itoh, MD, PhD, Emmy Yanagita, MT, Naoko Imagawa, MT, and Yoshihiro Kakeji, MD, PhD

Abstract: We have recently developed a new method called the immunohistochemistry-based cell cycle detection (iCCD), which allows the determination of cell cycle phases on a cell-by-cell basis. This automated procedure can be performed on tissue sections and involves triple immunostaining for geminin, cdt1, and γ H2A.X, which are nuclear proteins expressed sequentially, with a few overlaps, during the cell cycle. In the current study, we applied this technique to resected specimens of colorectal neoplasm to determine the usefulness of iCCD for the pathological examination of colorectal cancers.

We examined 141 cases of colorectal cancers. Normal mucosa and adenomas were analyzed as controls.

In nonneoplastic mucosa, we observed a pattern of distribution of the cells positive for these cell cycle markers. Adenomas showed a slight distortion in this pattern, the geminin-positive cells, indicative of S/G2/M phase, were localized in the upper one-third region of the crypts. In nonneoplastic mucosa, the marker expression pattern was disorganized. Compared with normal mucosa, colorectal neoplasms showed an increased proportion of geminin-positive cells and decreased percentages of cdt1-positive cells (G1 phase). However, we did not find significant difference in the expression pattern between adenomas and carcinomas. Cellular proportions were correlated with clinicopathological parameters such as microscopic vascular invasion and pT stages. In cases of preoperative adjuvant therapy, the proportion of geminin-positive cells decreased, whereas that of γ H2A.X-positive cells (indicative of apoptosis/degeneration) increased significantly.

We believe that this novel method can be applied to clinical samples to evaluate cell cycle kinetics and the effects of preoperative adjuvant therapy in colorectal cancers.

(Medicine 94(4):e501)

Abbreviations: Ag–Ab = antigen–antibody, iCCD = immunohistochemistry-based cell cycle detection, mTRG = modified tumor regression grade, RFS = recurrence-free survival, TNM = tumor–lymph node–metastasis.

INTRODUCTION

Colorectal cancers are one of the most common malignancies observed world over. A multidisciplinary approach is crucial for management of patients with colorectal neoplasms. Pathologists play a central role in the preoperative diagnosis and tumor-stage identification based on resected specimens. Recent advances in technology have enabled us to examine tissue samples at the molecular level. Immunostaining for drug targets (eg, epidermal growth factor receptor) and gene (KRAS) mutation analysis are new part of routine practice. Assuming a continuation in this trend, many investigators are developing new molecular pathology based techniques that provide valuable information to supplement conventional histological findings.

Cell growth is tightly regulated by cell cycle related genes. Uncontrolled cell growth leads to tumorigenesis or aggressive behavior of cancer cells.1 How the cell cycle is regulated in malignant neoplasms remains a topic in the field of cancer research. A gene, cell-cycle-related and expression-elevated protein in tumor (CREPT), was recently identified as a novel regulator of cell cycle by a database homology screening.2 CREPT promotes the G1 to S phase transition by regulating expressions of cell cycle related genes including cyclin D1. CREPT is overexpressed in various malignant neoplasms including colorectal cancers, suggesting that this gene is involved in tumor development and progression.2

We recently developed a new method called immunohistochemistry-based cell cycle detection (iCCD) method, which allows us to determine cell cycle phases on a cell-by-cell basis.2 This tissue section based approach is applicable to formalin-fixed and paraffin-embedded specimens. The triple immunostaining is an automated process and used 3 primary antibodies against geminin (a marker for S, G2, and M phases),3 cdt1 (G1),4,5 and γ H2A.X (cellular apoptosis and degeneration),6 which are nuclear proteins expressed sequentially, with a few overlaps, during the cell cycle. Impaired expression of cdt1 and geminin indicates tumor development and poor prognosis for several types of cancer, including colorectal carcinoma.6,8–10

In this study, we analyzed resected specimens of colorectal neoplasms by the iCCD method to validate its usefulness in the pathological evaluation of colorectal tumors.

MATERIALS AND METHODS

Patients

We included 141 patients with colorectal carcinoma in this study. These patients underwent surgical resection at the
Division of Gastrointestinal Surgery, Kobe University Hospital, between January 2009 and September 2013. Cases of special histological types (ie, mucinous adenocarcinoma, squamous cell carcinoma) were excluded because of their particularity. All patients provided their informed consent to the pathological examination of resected specimens, and the Clinical Ethics Committee of Kobe University Graduate School of Medicine approved this study.

Specimen Preparation

The tissue specimens were fixed in 10% buffered neutral formalin and embedded in paraffin. We used 4-μm-thick sections for the iCCD. Pathological specimens were evaluated based on the Dukes system and tumor–lymph node–metastasis (TNM)-based classification. Effects of preoperative therapy were assessed based on the modified tumor regression grade (mTRG). Nonlesional mucosa were sampled from 3 cases as controls. Nine resected specimens showed adenomas localized outside the carcinoma. These benign tumors were examined separately.

Single Immunostaining

Immunostaining was performed using an autostainer Bond Max (Leica Microsystems, Wetzlar, Germany) according to the preinstalled protocol. Primary antibodies were against geminin (GMNN, C2; Proteintech Group Inc, Chicago, IL), cdt1 (CDT1, C2; GeneTex, Irvine, CA), and γ H2A.X antibodies (P-Histone H2A.X, C20; Cell Signaling Technology, Danvers, MA). Deparaffinized sections were heat-treated for 10 or 20 minutes.

Immunohistochemistry-Based Cell Cycle Detection

The iCCD procedure was performed using an automated immunostainer (BOND-MAX, Leica Microsystems, Wetzlar, Germany) by a method described previously. All incubations were at room temperature, unless specified otherwise. The sections were deparaffinized and pretreated on a hot plate with citric acid buffer (pH 6.0, 100°C) for antigen retrieval. After a 10-minute incubation with 3% peroxidase blocking agent, the sections were incubated with antigeminin rabbit antibody

| Variables                      | n | Geminin Average, % | P Value | Cdt1 Average, % | P Value | γ H2A.X Average, % | P Value |
|--------------------------------|---|--------------------|---------|-----------------|---------|--------------------|---------|
| Patients total                 | 101 |                    |         |                 |         |                    |         |
| Sex                           |     |                    |         |                 |         |                    |         |
| Male                          | 47  | 34.049             | NS      | 64.660          | NS      | 1.291              | NS      |
| Female                        | 54  | 34.004             |         | 61.794          |         | 1.202              |         |
| Location                      |     |                    |         |                 |         |                    |         |
| C                             | 12  | 37.680             | NS      | 61.894          | NS      | 0.426              | NS      |
| A                             | 21  | 37.310             |         | 61.774          |         | 0.917              |         |
| T                             | 18  | 36.234             |         | 62.529          |         | 1.237              |         |
| D                             | 5   | 34.717             |         | 64.816          |         | 0.467              |         |
| S                             | 45  | 34.157             |         | 64.140          |         | 1.703              |         |
| Histology                     |     |                    |         |                 |         |                    |         |
| G1                            | 25  | 34.869             | NS      | 63.972          | NS      | 1.159              | NS      |
| G2                            | 69  | 36.245             |         | 62.367          |         | 1.387              |         |
| G3                            | 7   | 32.268             |         | 67.607          |         | 0.125              |         |
| pT category                   |     |                    |         |                 |         |                    |         |
| pT1                           | 5   | 34.483             | NS      | 64.758          | NS      | 0.759              | NS      |
| pT2                           | 26  | 34.578             |         | 63.738          |         | 1.684              |         |
| pT3                           | 49  | 37.020             |         | 62.129          |         | 0.851              |         |
| pT4a                          | 18  | 32.263             |         | 65.720          |         | 2.017              |         |
| pT4b                          | 3   | 44.121             |         | 55.880          |         | 0.000              |         |
| pN category                   |     |                    |         |                 |         |                    |         |
| 0                             | 61  | 35.458             | NS      | 63.358          | NS      | 1.184              | NS      |
| 1                             | 28  | 35.041             |         | 63.847          |         | 1.111              |         |
| 2                             | 12  | 37.869             |         | 60.278          |         | 1.853              |         |
| cM category                   |     |                    |         |                 |         |                    |         |
| 0                             | 83  | 36.286             | NS      | 62.475          | NS      | 1.216              | NS      |
| 1a                            | 12  | 33.113             |         | 65.412          |         | 1.475              |         |
| 1b                            | 6   | 31.572             |         | 67.264          |         | 1.163              |         |
| Dukes system                  |     |                    |         |                 |         |                    |         |
| A                             | 23  | 35.076             | NS      | 63.169          | NS      | 1.755              | NS      |
| B                             | 38  | 35.689             |         | 63.472          |         | 0.838              |         |
| C                             | 40  | 35.890             |         | 62.776          |         | 1.334              |         |
| ly                            |     |                    |         |                 |         |                    |         |
| Negative                      | 55  | 34.224             | NS      | 64.413          | NS      | 1.363              | NS      |
| Mild                          | 43  | 36.747             |         | 62.096          |         | 1.157              |         |
| Extended                      | 4   | 45.373             |         | 54.335          |         | 0.292              |         |
| v                             |     |                    |         |                 |         |                    |         |
| Negative                      | 52  | 35.444             | 0.007   | 64.178          | 0.008   | 1.379              | NS      |
| Mild                          | 47  | 37.556             | 0.010   | 63.098          | 0.012   | 1.146              |         |
| Extended                      | 2   | 63.479             |         | 36.521          |         | 0.000              |         |
| Recurrence                    |     |                    |         |                 |         |                    |         |
| (+)                           | 16  | 35.455             | NS      | 63.198          | NS      | 1.347              | NS      |
| (−)                           | 85  | 35.742             |         | 63.640          |         | 0.618              |         |

G1 = well-differentiated adenocarcinoma, G2 = moderately differentiated adenocarcinoma, G3 = poorly differentiated adenocarcinoma, H2A.X = ??, ly = lymphatic infiltration, NS = not significant, v = venous infiltration.
GMNN, ×100; Proteintech Group Inc) for 40 minutes followed by the secondary antibody MACH 2 Double Stain 2 (Biocare Medical, Concord, CA) for 30 minutes. A blue staining pattern was obtained using the PermaBlue/AP chromogen system (Diagnostic Biosystems, Pleasanton, CA). We heated the slides in citric acid buffer (pH 6.0) for 3 minutes at 100°C to stop the antigen–antibody (Ag–Ab) reaction and for additional antigen retrieval. The sections were incubated with anti-cdt1 rabbit antibody (CDT1, ×500; GeneTex) for 60 minutes followed by the secondary antibody MACH 2 Double Stain 2 (40 minutes) and the alkaline phosphatase coloring agent PermaRed/AP (Diagnostic Biosystems) (10 minutes). The tissues were incubated for 5 minutes with a denaturing solution (Biocare Medical) to terminate the cdt1 Ag–Ab reaction. Subsequently, they were incubated for 80 minutes with rabbit antibody against γ H2A.X antibodies (P-Histone H2A.X, ×20; Cell Signaling Technology) followed by 40 minutes with the secondary antibody MACH 2 Double Stain 1 (Biocare Medical). Finally, brown-colored staining pattern was obtained using 3,3′-diaminobenzidine4 hydrochloride (Invitrogen, Grand Island, NY). After completion of the staining process, the specimens were sealed with Marinol (Muto Pure Chemicals, Tokyo, Japan).

### Statistical Analysis

Positive cells were counted in randomly selected high-power fields (200×). Cell counts were totaled and converted into ratios. The proportion of positive cells for each marker were correlated with clinicopathological parameters (tumor locations, degrees of tumor differentiation, TNM classification, Dukes stages, lymphatic infiltration, venous infiltration, and recurrence) based on the Student t tests (2 groups) and Tukey–Kramer tests (multiple groups) using JMP 11 (SAS Institute Inc, Cary, NC). The iCCD results from patients with or without preoperative adjuvant therapy were also compared. Significance was defined as P < 0.05.

### RESULTS

#### Patient Characteristics

Of the 141 patients examined in this study, 129 were treatment-naïve (colon cancer, n = 101; rectal cancer, n = 28); the remaining 12 received preoperative adjuvant chemotherapy or chemoradiotherapy (colon cancer, n = 4; rectal cancer, n = 8). Patients’ characteristics are presented in Tables 1 and 2. Of the 101 cases of colon cancers without

| Variables       | n  | Geminin average (%) | P Value | Cdt1 average (%) | P Value | γ H2A.X average (%) | P Value |
|------------------|----|---------------------|---------|------------------|---------|---------------------|---------|
| Patients total   | 28 |                     |         |                  |         |                     |         |
| Sex              |    |                     |         |                  |         |                     |         |
| Male             | 20 | 29.663              | NS      | 66.952           | NS      | 3.326               | NS      |
| Female           |  8 | 29.722              |         | 66.597           |         | 3.740               |         |
| Location         |    |                     |         |                  |         |                     |         |
| Rs               |  8 | 32.592              | NS      | 65.506           | NS      | 1.902               | NS      |
| Ra               | 11 | 32.043              |         | 64.428           |         | 3.529               |         |
| Rb               |  9 | 23.016              |         | 70.893           |         | 6.090               |         |
| Histology        |    |                     |         |                  |         |                     |         |
| G1               |  5 | 21.030              | NS      | 68.739           | NS      | 10.231              | 0.045   |
| G2               | 22 | 31.708              |         | 66.008           |         | 2.285               |         |
| G3               |  1 | 28.311              |         | 71.690           |         | 0.000               |         |
| pT category      |    |                     |         |                  |         |                     |         |
| pT1              |  2 | 45.016              | 0.0052  | 53.428           | NS      | 1.556               | NS      |
| pT2              |  8 | 27.410              | 0.0084  | 68.332           | 4.259   |
| pT3              | 15 | 11.795              |         | 65.324           | 1.821   |
| pT4a             |  3 | 8.972               |         | 78.066           | 12.308  |
| pT4b             |  0 | N/A                 |         | N/A              |         |                     |         |
| pN category      |    |                     |         |                  |         |                     |         |
| 0                | 10 | 27.678              | NS      | 68.741           | NS      | 3.581               | NS      |
| 1                | 12 | 30.641              |         | 64.889           | 4.469   |
| 2                |  6 | 31.093              |         | 66.913           | 1.995   |
| cM category      |    |                     |         |                  |         |                     |         |
| 0                | 24 | 28.998              | NS      | 67.234           | NS      | 3.768               | NS      |
| 1a               |  3 | 38.801              |         | 58.131           | 3.069   |
| 1b               |  1 | 18.667              |         | 79.556           | 1.777   |
| Dukes system     |    |                     |         |                  |         |                     |         |
| A                |  4 | 25.923              | NS      | 68.617           | NS      | 5.460               | NS      |
| B                |  6 | 28.857              |         | 68.824           | 2.329   |
| C                | 18 | 30.792              |         | 65.564           | 3.645   |
| Ly               |    |                     |         |                  |         |                     |         |
| negative         | 19 | 26.511              | NS      | 68.758           | NS      | 4.730               | NS      |
| mild             |  8 | 38.580              |         | 60.200           | 1.220   |
| extended         |  1 | 18.667              |         | 79.556           | 1.778   |
| v                |    |                     |         |                  |         |                     |         |
| negative         |  8 | 25.303              | NS      | 67.528           | NS      | 7.169               | NS      |
| mild             | 19 | 31.221              |         | 66.678           | 2.092   |
| extended         |  1 | 35.407              |         | 60.287           | 4.306   |
| Recurrence       |    |                     |         |                  |         |                     |         |
| (+)              |  5 | 29.348              | NS      | 66.858           | NS      | 3.794               | NS      |
| (−)              | 23 | 32.560              |         | 65.212           | 2.228   |

G1 = well-differentiated adenocarcinoma, G2 = moderately differentiated adenocarcinoma, G3 = poorly differentiated adenocarcinoma, ly = lymphatic infiltration, N/A = not available, NS = not significant, v = venous infiltration.
preoperative adjuvant chemotherapy, 5 were classified as pT1 (submucosal layer invasion), 26 as pT2 (muscularis propria invasion), 49 as pT3 (subserosal invasion), 18 as pT4a (involvement of the visceral peritoneum), and 3 as pT4b (invasion of other organs or structures). Rectal cancers without preoperative treatment were classified as pT1 with lymph node metastasis (n = 2), pT2 (n = 8), pT3 (n = 15), and pT4a (n = 3). Of the 12 patients who had received preoperative chemotherapy, 6 patients with rectal cancer received preoperative chemoradiotherapy, whereas the remaining 6 received only chemotherapy.

**Correlation Between Single Immunostaining and iCCD**

To validate findings of iCCD, its staining pattern was compared with those of single immunostaining. As shown in Figure 1, the tumor cells positive for geminin, cd1, or γ H2A.X

![Comparison of conventional immunohistochemistry with single antibody and iCCD method. Single immunostaining for geminin (A, ×200), cd1 (B, ×200), and γ H2A.X (C, ×200) shows randomly distributed positive cells. iCCD (D, ×200) on the same case reveals the cells immunoreactive for geminin (blue), cd1 (red), and γ H2A.X (brown, arrow head). The immunoreactive cells appear to be similar in number and distribution between the 2 methods. cd1 = ??, H2A.X = ??, iCCD = immunohistochemistry-based cell cycle detection.](image1.jpg)

![Pattern diagram of typical distribution in different tissue type. These figures were views showing a frame format of 3 kinds of cells. Their polarity was more disturbed in adenoma than in normal mucosa, and even worse in adenocarcinoma.](image2.jpg)
were similar in numbers and distribution between the 2 methods, suggesting that the triple immunostaining could be a useful tool to assess cell cycles on tissue sections.

**iCCD Findings in Nonlesional and Neoplastic Epithelia**

The iCCD method stains geminin blue, cdt1 red, and γ H2A.X brown. The staining patterns of these nuclear markers clearly differed between healthy and neoplastic tissues (Figure 2). In the nonneoplastic mucosa, iCCD highlighted a well-organized distribution of positive cells. Geminin-positive epithelial cells (S/G2/M phases) were noted mainly at the bottom of crypts (Figure 3A and B), whereas cdt1-positive cells (G1 phase) were distributed widely throughout the crypts. Cells undergoing apoptosis or degeneration (positive for γ H2A.X) were confined to the epithelial surface.

In colorectal tumors, all 3 types of cells were also observed, but without a specific distribution pattern. In adenomas (Figure 3A), the geminin-positive cells were localized to the upper one-third region of the crypts. However, 3 cell-types were almost randomly distributed in carcinomas (Figure 3B and C). Cells positive for each marker appeared to vary in number and distribution among cases. Furthermore, their counts varied with location even within a single tumor. Colorectal neoplasms showed an increase in the proportion of geminin-positive cells and a decrease in percentage of cdt1-positive cells compared with nonneoplastic mucosa (Figure 4). The proportion of cdt1-positive cells in colon cancers was significantly lower than that in colonic adenomas \((P = 0.048)\). We did not observe any other significant differences in the cellular proportions between adenomas and carcinomas.

**Associations Between iCCD Findings and Clinicopathological Features in Colon Cancer**

We correlated the iCCD results with clinicopathological parameters in patients with colon cancers who did not receive preoperative therapy (Table 1). The percentage of geminin-positive cells was significantly higher in patients with extensive venous infiltration compared with those with no or mild venous infiltration \((P = 0.007\) and \(P = 0.010\), respectively). Conversely, extensive venous infiltration was associated with decreased percentages of cdt1-positive cells. Approximately, 15% of the patients with colon cancers reported recurrence at 0.5 to 36 months after surgery (median 6 months). The percentage of γ H2A.X-positive cells in such patients was slightly higher compared with those without a relapse (Figure 5).

**Associations Between iCCD Findings and Clinicopathological Features in Rectal Cancer**

We performed similar association analyses for 28 patients with rectal cancers who did not receive preoperative adjuvant chemotherapy (Table 2). Percentages of geminin-positive cells showed negative correlations with depth of tumor invasion (pT1 vs pT4, \(P = 0.0052\); pT2 vs pT4, \(P = 0.0084\)). In addition, the percentages of γ H2A.X-positive cells in well-differentiated cancers were significantly lower than that in moderately differentiated tumors \((P = 0.045)\). There was a weak association...
FIGURE 4. Expression of cell cycle markers in different tissue types. Data are expressed as the percentage of cells positive for geminin, cdt1, or γH2A.X in normal and abnormal tissue specimens from the colon (N = 101) and rectum (N = 28). All 3 markers were more commonly detected in adenoma and carcinoma than in normal tissue, except γH2A.X in colon tumors. H2A.X = ??, RFS = recurrence-free survival.

FIGURE 5. Relationship between the RFS and cell cycle kinetics. This graph plotted about the RFS and 3 phases of cells, in the patients having a recurrence. No strong correlation was found, but between the rates of γH2A.X and the term to relapse, there may be negative correlation. H2A.X = ??, RFS = recurrence-free survival.
between the increasing of the ratio of $\gamma$ H2A.X-positive cells and shortening of recurrence-free survival (RFS) (Figure 4).

**Impact of Preoperative Therapy on Cell Cycle Kinetics in Colorectal Cancer**

The preoperative chemotherapy was either pyrimidine fluoridate or platinum-based (Table 3). Additional radiotherapy was for patients suspected with a locally advanced tumor (T4) or metastasis in the lateral pelvic lymph node. Irradiation schedule involved 25 sessions of 1.8 Gy each. The patients subsequently underwent radical surgery with lymph node dissections. Representative iCCD findings for colorectal cancer with preoperative therapy are shown in Figure 3D. Preoperative therapy significantly reduced the proportion of geminin-positive cells (colon cancers, $P = 0.006$; rectal cancers, $P = 0.047$). As anticipated, the percentage of $\gamma$ H2A.X-positive cells increased significantly (colon cancers, $P < 0.0001$; rectal cancers, $P = 0.039$) (Table 4). However, mTRGs did not correlate with the proportion of cells positive for cell cycle markers, with the exception of reduced proportion of cdt1-positive (G1 phase) cells in mTRG4 rectal cancers (mTRG2 vs mTRG4, $P = 0.0098$). No discernible difference was found in the iCCD results between the chemotherapy and chemoradiotherapy groups.

**Discussion and Conclusion**

Various molecules are involved in the development and progression of neoplasms.14,15 Researchers have made several

### TABLE 3. Demographics and Tumor Characteristics of Patients Who Received Preoperative Therapy

| No. | Age | Sex  | Location                       | Histology | pT | pN | cM | Preoperative Therapy | Regimen   | mTRG |
|-----|-----|------|--------------------------------|-----------|----|----|----|----------------------|-----------|------|
| 1   | 49  | Female | A                               | G2        | 3  | 0  | 1a | CT                   | XEROX     | 4    |
| 2   | 63  | Male | Peritoneal dissemination of colon cancer | G2        | N/A | N/A | N/A | CT                   | N/A       | 4    |
| 3   | 57  | Male | S                               | G1        | 3  | 1  | 1a | C                    | CT        | mF6  |
| 4   | 63  | Female | C                               | G2        | 3  | 0  | 1a | B                    | CT        | mF6, 5-FU/LV | 4  |
| 5   | 59  | Male | Rb                              | G2        | 3  | 0  | 0  | B                    | CRT       | UFT/LV | 3   |
| 6   | 76  | Male | Rb                              | G2        | 3  | 0  | 0  | B                    | CRT       | UFT/LV | 3   |
| 7   | 63  | Male | Rb                              | G2        | 3  | 0  | 0  | B                    | CRT       | UFT/LV | 2   |
| 8   | 64  | Female | RbP                             | G2        | 3  | 0  | 0  | B                    | CRT       | N/A   | 4   |
| 9   | 63  | Male | Local recurrence of rectal cancer | G1        | N/A | N/A | N/A | N/A                  | CT        | XEROX | 4   |
| 10  | 62  | Male | RbP                             | G2        | 4b | 2  | 1a | C                    | CT        | mF6   | 4   |
| 11  | 67  | Male | Rb                              | G2        | 3  | 2  | 0  | C                    | CRT       | UFT/LV | 3   |
| 12  | 70  | Male | Rb                              | G2        | 3  | 2  | 1a | C                    | CRT       | UFT/LV | 2   |

5-FU = fluorouracil, CRT = chemoradiotherapy, CT = chemotherapy, G1 = well-differentiated adenocarcinoma, G2 = moderately differentiated adenocarcinoma, H2A.X = ??, LV = leucovorin, ly = lymphatic infiltration, mF6 = modified FOLFOX6, mTRG = modified tumor regression grade, N/A = not available, UFT = uracil-tegafur, v = venous infiltration, XEROX = capecitabine and oxaliplatin.

### TABLE 4. Impact of Preoperative Therapy of Cell Cycle Kinetics

| Variables                     | n     | Geminin Average, % | $P$ Value | Cdt1 Average, % | $P$ Value | $\gamma$ H2A.X Average, % | $P$ Value |
|-------------------------------|-------|--------------------|-----------|-----------------|-----------|--------------------------|-----------|
| Colon cancer                  | None  | 35.6291            |           | 63.1276         |           | 8.62268                  |           |
| mTRG                          | CT    | 16.5567            | 0.006     | 74.8206         | 0.0795    | 8.62268                  | 0.0001    |
|                               | 2     | 27.6596            | NS        | 65.9574         | NS        | 6.38298                  | NS        |
|                               | 3     | 0                  | N/A       | N/A             |           | N/A                      |           |
|                               | 4     | 12.8558            | 77.775    |                  |           | 9.36925                  |           |
| Rectal cancer                 | None  | 29.6795            | 0.0469    | 66.6986         | 0.3155    | 3.62188                  | 0.039     |
| mTRG                          | CT    | 20.8915            |           | 66.5665         |           | 2.379                    |           |
|                               | CRT   | 19.1946            |           | 72.6276         |           | 5.74902                  |           |
|                               | 2     | 9.663              | NS        | 80.2116         |           | 10.1254                  |           |
|                               | 3     | 4                  | 71.3266   | 4.528           |           | 13.7706                  |           |
|                               | 4     | 21.9907            | 64.2388   |                |           | 0.0098                   | 0.048     |

CRT = chemoradiotherapy, CT = chemotherapy, H2A.X = ??, mTRG = modified tumor regression grade, N/A = not available, NS = not significant.
efforts to visualize these key molecular events on resected tissue sections. Two immunohistochemical markers commonly used in routine practice are Ki-67 and p53. Increased number of Ki-67-labeling indices represent increased proliferation and can indicate neoplastic transformation under appropriate settings. Diffused nuclear expression of p53 usually suggests a malignant transformation. However, these immunostaining results are often difficult to interpret, because similar patterns are observed even under inflammatory conditions. Recently, multicolor immunostaining has found acceptance in routine analysis. Availability of automated immunostainers with reproducible staining protocols has made it theoretically possible to stain 2 or 3 different molecules in a single section.

The present study was based on a multicolor immunostaining procedure and highlighted differences in the cell cycle kinetics between healthy and neoplastic colorectal tissues. The iCCD method demonstrated that, in normal mucosa, geminin-positive cells (S/G2/M phase cells) were localized at the bottom of crypts, whereas cdt1-positive cells (G1 phase cells) were localized in the middle and upper portions. In contrast, the geminin-positive cells in adenomatous mucosa were found in the middle and upper regions, suggesting disorganized cell cycle kinetics in these crypts. This finding supports a mode of colorectal tumorigenesis, in which, stem cells with adenomatous polyposis coli mutation are proposed to proliferate in lower crypt and move toward the surface of the mucosa, as they lose their capacity to divide and differentiate.

In cancerous tissue, cell cycle kinetics seemed strikingly distorted as indicated by the randomly distributed immunomarker-positive cells. Furthermore, the numbers of cells positive for each marker varied with location, even within a single tumor, indicating their very heterogeneous cell cycle activities.

We correlated the iCCD results with clinicopathological parameters. We found that the proportion of geminin-positive cells to be associated with microscopic vascular invasion in colon cancers and negatively correlated with depth of tumor invasion in rectal cancers. Venous infiltration is a well-known predictive factor of metastasis or recurrence in patients with colorectal carcinoma. All the patients showing extensive venous infiltration presented with tumor recurrence within 17 months after surgery, in spite of postoperative chemotherapy. Although we noted several differences among tissues, interpretation of iCCD results was not as easy as we previously expected. One possible reason is the significant variability in iCCD findings among cases.

Preoperative adjuvant chemotherapy is increasingly used for patients with advanced colorectal cancer. Therapeutic effects are currently assessed only based on the area of residual tumors and degree of necrosis. Distinguishing viable cancer cells from those undergoing the apoptotic or necrotic process is also challenging.

The iCCD method may help estimate for patients with advanced colorectal cancer. Therapeutic significance in iCCD findings among cases. Therapeutic variability in iCCD findings among cases. Therapeutic significance in iCCD findings among cases. Therapeutic variability in iCCD findings among cases. Therapeutic variability in iCCD findings among cases. Therapeutic variability in iCCD findings among cases.

As described above, CREPT was recently found to be a novel regulator of the cell cycle. In the original study, the overexpression of CREPT was confirmed in various tumors including colorectal cancers, and its expression was negatively correlated with prognosis of patients with gastric cancer. CREPT seems to promote the G1 to S phase transition by regulating expressions of cyclins and cyclin-dependent kinases, eventually leading to shortening of the cell cycle in malignant cells. As expected by the CREPT study, iCCD nicely demonstrated that the proportion of geminin-positive cells (S, G2, and M phases) is increased, and the percentage of cdt1-positive cells (G1 phase) was decreased in colon cancers.

One limitation of this study is that some groups, particularly the preoperative therapy group, had small numbers of patients. We could not examine more cases, because we found that the iCCD method frequently fails to work on tissues stored for >3 years. A similar problem has been previously reported for another nuclear antigen. Although iCCD is automated, it requires nearly thrice the number of steps as in conventional immunostaining. This limitation makes the procedure longer and can induce tissue damage. A potential solution is to use cocktail antibodies, wherein tissue sections are incubated with multiple antibodies at the same time. However, to make this approach feasible, the antibodies should be derived from different species. Currently, all antibodies used for iCCD are rabbit-derived and polyclonal. The cocktail treatment can be considered when a mouse monoclonal antibody becomes available for at least 1 of the 3 markers.

In conclusion, we examined the cell cycle kinetics of colorectal neoplasms using a fully automated, section-based procedure. Our iCCD findings correlated with some clinicopathological features of colorectal cancer. This novel method might also help us to evaluate the effects of preoperative therapy. We recommended this automated multicolor immunostaining as a reliable tool to assess tissue samples in a clinical oncology setting.

ACKNOWLEDGMENTS

The authors thank Yoshiharu Ohno, MD, PhD, specially appointed Professor, Kobe University (Department of Radiology, Kobe University Graduate School of Medicine), and Yoh Zen, MD, PhD, specially appointed Professor, Kobe University (Department of Pathology, Kobe University Graduate School of Medicine) for their valuable contributions.

REFERENCES

1. Hanahan and Weinburg. The hallmarks of cancer. Cell. 2000;100:57–70.
2. Lu D, Wu Y, Wang Y, et al. CREPT accelerates tumorigenesis by regulating the transcription of cell-cycle-related genes. Cancer Cell. 2012;21:92–104.
3. Yanagita E, Kamoshida S, Imagawa N, et al. Immunohistochemistry-based cell cycle detection (iCCD): a novel system to visualize cell kinetics on formalin-fixed paraffin-embedded tissues. Am J Surg Pathol. 2012;36:769–773.
4. Hofmann JF, Beach D. Cdt1 is an essential target of the Cdc10/Sct1 transcription factor: requirement for DNA replication and inhibition of mitosis. EMBO J. 1994;13:425–434.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
5. Nishitani H, Taraviras S, Lygerou Z, et al. The human licensing factor for DNA replication Cdt1 accumulates in G1 and is destabilized after initiation of S-phase. J Biol Chem. 2001;276:44905–44911.

6. Xouri G, Lygerou Z, Nishitani H, et al. Cdt1 and geminin are down-regulated upon cell cycle exit and are over-expressed in cancer-derived cell lines. *Ear J Biochem.* 2004;271:3368–3378.

7. Lu C, Zhu F, Cho YY, et al. Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. *Mol Cell.* 2006;23:121–132.

8. Petropoulou C, Kotantaki P, Karamitros D, et al. Cdt1 and Geminin in cancer: markers or triggers of malignant transformation? *Front Biosci.* 2008;1:4485–4494.

9. Lu C, Zhu F, Cho YY, et al. Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. *Mol Cell.* 2006;23:121–132.

10. Nishihara K, Shomori K, Tamura T, et al. Immunohistochemical expression of geminin in colorectal cancer: implication of prognostic significance. *Oncol Rep.* 2009;21:1189–1195.

11. Gemsenjäger E. The classification system of Dukes and its modification for rectal and colonic cancers. *Helv Chir Acta.* 1981;48:265–272.

12. Hamilton SR, Bosman FT, Boffetta P, et al. Tumours of the colon and rectum. In: Bosman FTF, Hruban RH, Theise NDCarneiro, eds. *WHO Classification of Tumours of the Digestive System.* 4th ed. Lyon: the International Agency for Research on Cancer; 2010. 131–182.

13. Chang HH, Leeper WR, Chan G, et al. Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. *Am J Surg Pathol.* 2012;36:570–576.

14. Rothberg PG. The role of the oncogene c-myc in sporadic large bowel cancer and familial polyposis coli. *Semin Surg Oncol.* 1987;3:152–158.

15. Gryfe R, Swallow C, Bapat B, et al. Molecular biology of colorectal cancer. *Curr Prob Cancer.* 1997;21:233–300.

16. Berenzi A, Benetti A, Bertalot G, et al. Ki67 immunohistochemical evaluation in colorectal cancer and normal colonic mucosa. Possible clinical applications. *Pathologica.* 1992;84:155–163.

17. van den Berg FM, Tigges AJ, Schipper ME, et al. Expression of the nuclear oncogene p53 in colon tumours. *J Pathol.* 1989;157:193–199.

18. Porschen R, Krögel A, Langen C, et al. Assessment of proliferative activity in carcinomas of the human alimentary tract by Ki-67 immunostaining. *Int J Cancer.* 1991;42:686–691.

19. Yanagita E, Imagawa N, Ohbayashi C, et al. Rapid multiplex immunohistochemistry using the 4-antibody cocktail YANA-4 in differentiating primary adenocarcinoma from squamous cell carcinoma of the lung. *Immunohistochem Mol Morphol.* 2011;19:509–513.

20. Shin YI, Sung NY, Lee YS, et al. The expression of multiple proteins as prognostic factors in colorectal cancer: cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67. *Gut Liver.* 2014;8:13–23.

21. Zhou ZH, Xu GF, Zhang WJ, et al. Reevaluating significance of perineural invasion in gastric cancer based on double immunohistochemical staining. *Arch Pathol Lab Med.* 2014;138:229–234.

22. Lamprecht SA, Lipkin M. Migrating colonic crypt epithelial cells: primary targets for transformation. *Carcinogenesis.* 2002;23:1777–1780.

23. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. *Ann Oncol.* 2007;18:299–304.

24. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer.* 2009;45:228–247.

25. Ribalt T, McCutcheon IE, Aldape KD, et al. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. *Am J Surg Pathol.* 2004;28:1532–1536.